Cingulate (CING) Competitors $4.32 +0.10 (+2.25%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$4.34 +0.02 (+0.46%) As of 02/21/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CING vs. ALXO, LTRN, PDSB, IMMX, OTLK, VNRX, STTK, ATRA, RPTX, and CNTBShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include ALX Oncology (ALXO), Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Outlook Therapeutics (OTLK), VolitionRx (VNRX), Shattuck Labs (STTK), Atara Biotherapeutics (ATRA), Repare Therapeutics (RPTX), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. ALX Oncology Lantern Pharma PDS Biotechnology Immix Biopharma Outlook Therapeutics VolitionRx Shattuck Labs Atara Biotherapeutics Repare Therapeutics Connect Biopharma ALX Oncology (NASDAQ:ALXO) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations. Does the media refer more to ALXO or CING? In the previous week, ALX Oncology had 1 more articles in the media than Cingulate. MarketBeat recorded 1 mentions for ALX Oncology and 0 mentions for Cingulate. ALX Oncology's average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score. Company Overall Sentiment ALX Oncology Neutral Cingulate Neutral Do institutionals and insiders believe in ALXO or CING? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 33.4% of ALX Oncology shares are held by company insiders. Comparatively, 17.1% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate ALXO or CING? ALX Oncology currently has a consensus price target of $3.05, indicating a potential upside of 173.54%. Cingulate has a consensus price target of $16.00, indicating a potential upside of 269.94%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Cingulate 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the MarketBeat Community believe in ALXO or CING? ALX Oncology received 42 more outperform votes than Cingulate when rated by MarketBeat users. However, 76.92% of users gave Cingulate an outperform vote while only 64.20% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5264.20% Underperform Votes2935.80% CingulateOutperform Votes1076.92% Underperform Votes323.08% Is ALXO or CING more profitable? ALX Oncology's return on equity of -93.02% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Cingulate N/A -570.20%-236.15% Which has preferable valuation and earnings, ALXO or CING? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.98-0.37CingulateN/AN/A-$23.53MN/AN/A Which has more risk and volatility, ALXO or CING? ALX Oncology has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500. SummaryALX Oncology beats Cingulate on 7 of the 12 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.59M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book-0.066.717.644.62Net Income-$23.53M$138.33M$3.18B$245.85M7 Day Performance-4.10%-2.61%-1.99%-2.68%1 Month Performance-14.02%-2.32%-0.42%-2.19%1 Year Performance289.64%-5.31%16.51%12.84% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.8593 of 5 stars$4.33+2.2%$16.00+269.9%+300.5%$13.59MN/A0.0020ALXOALX Oncology3.2607 of 5 stars$1.04-4.6%$3.05+193.3%-93.0%$54.85MN/A-0.3540LTRNLantern Pharma0.4623 of 5 stars$5.05-0.4%N/A+10.2%$54.44MN/A-2.8420News CoverageNegative NewsPDSBPDS Biotechnology1.0382 of 5 stars$1.45-0.7%$11.67+704.6%-74.7%$54.24MN/A-1.2520News CoverageIMMXImmix Biopharma2.6022 of 5 stars$1.97-2.0%$7.00+255.3%-41.1%$54.20MN/A-2.329High Trading VolumeOTLKOutlook Therapeutics2.066 of 5 stars$1.69-1.2%$27.40+1,521.3%-81.3%$54.05MN/A-0.1920Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpVNRXVolitionRx1.8945 of 5 stars$0.58-3.3%$3.75+546.6%-43.1%$53.75M$770,000.00-1.6180STTKShattuck Labs3.5461 of 5 stars$1.12-5.1%$8.67+673.8%-84.4%$53.47M$1.66M-0.73100News CoverageATRAAtara Biotherapeutics4.3225 of 5 stars$9.26-8.0%$17.75+91.7%-64.3%$53.34M$8.57M-0.36330RPTXRepare Therapeutics2.9985 of 5 stars$1.20flat$7.00+483.3%-79.0%$51.01M$51.13M-0.60180Upcoming EarningsCNTBConnect Biopharma2.9778 of 5 stars$0.92-6.6%$8.00+768.9%-24.3%$50.87MN/A0.00110 Related Companies and Tools Related Companies ALX Oncology Competitors Lantern Pharma Competitors PDS Biotechnology Competitors Immix Biopharma Competitors Outlook Therapeutics Competitors VolitionRx Competitors Shattuck Labs Competitors Atara Biotherapeutics Competitors Repare Therapeutics Competitors Connect Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CING) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
